33
c
18
3b
14
10
32
46
19
Janos L. Tanyi
61 16
19
1
49
2
1c
1b
1d
18
2c
87
1d
2 29
1d
25
Janos L. Tanyi
78
87
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
28
9e
3
70
Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
11
Department: Obstetrics and Gynecology
4
1
b
1d
46
Contact information
55
4
3
3
3
2
4
b
1f
55
Department of Obstetrics and Gynecology
34 Jordan Center for Gynecologic Cancer at Penn
2d Perelman Center for Advanced Medicine
46 3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
26
34 Jordan Center for Gynecologic Cancer at Penn
2d Perelman Center for Advanced Medicine
46 3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
2e
Office: 215-662-3318
32 Fax: 215-349-5849
24
95
32 Fax: 215-349-5849
24
Email:
janos.tanyi@uphs.upenn.edu
12
janos.tanyi@uphs.upenn.edu
13
Education:
21 9 M.D. 1c (Summa cum Laude) c
4e University of Debrecen, Faculty of Medicine, Hungary , 1993.
21 a Ph.D. 1c (Summa cum Laude) c
73 Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
c
3
3
21
21 9 M.D. 1c (Summa cum Laude) c
4e University of Debrecen, Faculty of Medicine, Hungary , 1993.
21 a Ph.D. 1c (Summa cum Laude) c
73 Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
c
1f
Post-Graduate Training
24 75 Residency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
24 83 Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
24 6d Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
24 4c Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, 2e Hospital of the University of Pennsylvania, 2b Philadelphia, PA, 2008-2011.
c
3
3
8d
Permanent link24 75 Residency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
24 83 Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
24 6d Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
24 4c Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, 2e Hospital of the University of Pennsylvania, 2b Philadelphia, PA, 2008-2011.
c
2 29
21
1e
1d
24
2b
29
27
23
17d Pavlatos E, Tate B, Nguyen A, Heller IS, Nasioudis D, Tanyi JL, Torigian DA, Rodriguez D, Domchek SM, Drapkin RI, Brown EJ, Mills GB, Simpkins F: Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy. AACR Annual Meeting, San Diego, CA Apr 2026.
1c8 Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek SM, Zhang L, Hu X: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
1c2 Hu X, Huang J, Yuan J, Sun Y, Wang Y, Hu Z, Jiang J, Wang Z, Wang B, Long M, Maxwell KN, Fan Y, Tanyi JL, Montone KT, Li H, Kim SH, Nathanson KL, Rebbeck TR, Domchek SM, Vonderheide RH, Zhang L: Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell Rep Page: 45(2):116882. doi: 10.1016/j.celrep.2025, Feb 2026.
1ca Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X: Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. Elife Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
26a Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL: Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther. Page: S1525-0016(26)00022-5. doi: 10.1016/j.ymthe.2026.01.021, Jan 2026.
248 Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med. Page: 6(9):102301. doi: 10.1016/j.xcrm.2025.102301, Sep 2025.
2ea Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ Jr, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD: Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. .Cancer Cell Page: 43(8):1568-1586.e10. doi: 10.1016, Aug 2025.
12b Gleason E, Pollie M, Satish S, Li S, Tanyi JL: Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report. Gynecol Oncol Rep Page: 60:101816. doi: 10.1016/j.gore.2025.101816, Aug 2025.
164 Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Page: 33(4):921-927. doi: 10.1177/10668969241291890, Jun 2025.
2c
7
1d
1f
Selected Publications
183 Dagher C, Huang A, Nasioudis D, Giuntoli II RL, Latif NA, Tanyi JL, Kim SH, Ko EM, Gysler SM, Martin LP: Clinical Activity of Metronomic Cyclophosphamide and Bevacizumabwithor without Pembrolizumab in Recurrent Ovarian Cancer: A Single-Institution Retrospective Analysis. SGO Annual Meeting, San Juan PR Apr 2026.17d Pavlatos E, Tate B, Nguyen A, Heller IS, Nasioudis D, Tanyi JL, Torigian DA, Rodriguez D, Domchek SM, Drapkin RI, Brown EJ, Mills GB, Simpkins F: Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy. AACR Annual Meeting, San Diego, CA Apr 2026.
1c8 Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek SM, Zhang L, Hu X: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
1c2 Hu X, Huang J, Yuan J, Sun Y, Wang Y, Hu Z, Jiang J, Wang Z, Wang B, Long M, Maxwell KN, Fan Y, Tanyi JL, Montone KT, Li H, Kim SH, Nathanson KL, Rebbeck TR, Domchek SM, Vonderheide RH, Zhang L: Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell Rep Page: 45(2):116882. doi: 10.1016/j.celrep.2025, Feb 2026.
1ca Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X: Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. Elife Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
26a Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL: Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther. Page: S1525-0016(26)00022-5. doi: 10.1016/j.ymthe.2026.01.021, Jan 2026.
248 Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med. Page: 6(9):102301. doi: 10.1016/j.xcrm.2025.102301, Sep 2025.
2ea Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ Jr, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD: Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. .Cancer Cell Page: 43(8):1568-1586.e10. doi: 10.1016, Aug 2025.
12b Gleason E, Pollie M, Satish S, Li S, Tanyi JL: Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report. Gynecol Oncol Rep Page: 60:101816. doi: 10.1016/j.gore.2025.101816, Aug 2025.
164 Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Page: 33(4):921-927. doi: 10.1177/10668969241291890, Jun 2025.
2c